This Study is to Estimate the Efficacy of Hemodialysis Alone for Uric Acid Clearance in Patients on Hemodialysis. In Order to Evaluate the Need of Adjuvant Uric Acid Lowering Therapy

NCT ID: NCT07144332

Last Updated: 2025-08-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-07-13

Study Completion Date

2026-02-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Background: Uricemia dramatically rises with the stage of chronic kidney disease (CKD) and correlates with its mortality. Hemodialysis (HD) being the most used treatment at the end stage kidney disease in Sohag governorate , we sought to evaluate its efficacy on the clearance of uric acid (UAc) when used alone and twice per week.

Methods: A cross-sectional study of all consenting patients with CKD stage 5 recruited at random during hemodialysis sessions at hemodialysis unit in Sohag university hospital from July to December 2025. We collected socio-demographic data, relevant clinical information, hemodialysis related variables, and measured serum uric acid (SUA) levels before and after the dialysis to assess the uric acid clearance. A clearance between 65 and 80% and above 80% was considered as low and good efficacy of hemodialysis respectively

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Aim of the the work The aim of this study is to estimate the efficacy of Hemodialysis alone for uric acid clearance in patients on hemodialysis. In order to evaluate the need of adjuvant uric acid lowering therapy

Patients And Methods

1. Type of The study:

Prospective cross-sectional study.
2. Place of the study:

Sohag University Hospital, department of Internal Medicine and hemodialysis unit.
3. Ethical aspect:

Informed Written consent will be taken from all patients to include their data in the study, the research will be approved by medical ethics committee of Faculty of Medicine, Sohag university

Patients:

Inclusion criteria:

• We included all consenting adults aged 18 or older, on maintenance hemodialysis for at least 3 consecutive months receiving 2 to 3 sessions weekly.

Exclusion criteria:

* Patients aged \< 18 years old .
* Patients on recent hemodialysis less than 3 months.
* We excluded patients who were on Uric acid lowering therapy (UALT).
* Patients received less than 4 hours of hemodialysis and those who had emergency dialysis.

Number of Patients:

The study will include 100 hemodialysis patients for duration of 6 months.

\* Methods We carried out a prospective cross-sectional study at the Hemodialysis unit in Sohag University Hospital . Patients included in the study dialyzed with the Fresenius® 4008S generator (Fresenius Medical Care, St. Wendel, Germany) dialyzers , with a polysulfone synthetic dialysis membrane and bicarbonate dialysate.

The size of the dialysis membrane was estimated according to the total body surface of the patient . Membranes sizes FX60 were used for a body surface of approximately (1.2-1.5 m2 ) ; whereas FX80 between (1.6 and 1.8m2 ) and FX100 were used for body surfaces above 1.8m2.

Dialysis adequacy was calculated from the formula Kt/ V urea; K being the clearance of urea given by the dialyzer, t the duration of the dialysis session (4 h) and V the distribution volume of urea \[10\].

Uric acid clearance (UAc) was estimated using the formula: UAc=100 x (SUA levels before HD-SUA levels after HD) / SUA levels before HD\] \[14\]. We defined two thresholds values for UAc (65 and 80%).

A Hemodialysis session was considered to be of low efficacy if below 65% of reduction, moderate efficacy between 65 and 80% and a good efficacy above 80% of UAc . \[15\].

These predictors will be included:

1. Gender.
2. Age.
3. Underlying nephropathy.
4. Average time on renal replacement therapy.
5. Comorbidities,
6. Residual renal function (\< 100 ml/24 or ≥ 100 ml/24 h) of participants.
7. Current hemodialysis session parameters such as vascular access.
8. Duration of the session.
9. Time interval between the current and previous dialysis session.
10. Body mass index (BMI).
11. Blood pressure at the beginning and at the end of dialysis
12. Dialysis adequacy.
13. Blood flow (\< 300ml/min or\>300ml/min).
14. Serum uric acid level which were assessed on a peripheral blood sample collected 5 min before and after dialysis.

Statistical analysis

* All collected data will be analyzed and correlated.
* All the statistical analysis will be done by using Statistical Package for Social Sciences (SPSS Inc., Chicago, IL) version20.
* Baseline data and patient characteristics will be presented using descriptive statistics, for example, number, percentage, mean and standard deviation.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hemodialysis Hyperuricemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* We included all consenting adults aged 18 or older, on maintenance hemodialysis for at least 3 consecutive months receiving 2 to 3 sessions weekly

Exclusion Criteria

1. Patients aged \< 18 years old .
2. Patients on recent hemodialysis less than 3 months.
3. We excluded patients who were on Uric acid lowering therapy (UALT).
4. Patients received less than 4 hours of hemodialysis and those who had emergency dialysis.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Sohag University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Reham Hussien Abotaleb

Internal medicine resident doctor

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Sohag university faculty of medicine

Sohag, , Egypt

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Reham Hussien, master

Role: CONTACT

00201092162739

Ali taha, Professor

Role: CONTACT

00201005871047

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Magdy M Amin, Professor

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Soh-Med-25-7-13MS

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.